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Abstract
Background: Echinacea spp. extracts and the derived phytocompounds have been shown to
induce specific immune cell activities and are popularly used as food supplements or nutraceuticals
for immuno-modulatory functions. Dendritic cells (DCs), the most potent antigen presenting cells,
play an important role in both innate and adaptive immunities. In this study, we investigated the
specific and differential gene expression in human immature DCs (iDCs) in response to treatment
with a butanol fraction containing defined bioactive phytocompounds extracted from stems and
leaves of Echinacea purpurea, that we denoted [BF/S+L/Ep].
Results: Affymetrix DNA microarray results showed significant up regulation of specific genes for
cytokines (IL-8, IL-1β, and IL-18) and chemokines (CXCL 2, CCL 5, and CCL 2) within 4 h after
[BF/S+L/Ep] treatment of iDCs. Bioinformatics analysis of genes expressed in [BF/S+L/Ep]-treated
DCs revealed a key-signaling network involving a number of immune-modulatory molecules leading
to the activation of a downstream molecule, adenylate cyclase 8. Proteomic analysis showed
increased expression of antioxidant and cytoskeletal proteins after treatment with [BF/S+L/Ep] and
cichoric acid.
Conclusion:  This study provides information on candidate target molecules and molecular
signaling mechanisms for future systematic research into the immune-modulatory activities of an
important traditional medicinal herb and its derived phytocompounds.
Background
Echinacea spp., commonly known as purple coneflower, is
indigenous to North America. The use of Echinacea spp. as
an herbal remedy originated in the medicinal culture of
North American Indians during the 17th century and was
later introduced to Europe. Its use became popular again
in the early 1990s and continues today. Currently, Echina-
cea extracts from whole plant or specific tissue (e.g., root
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or aerial parts) are among the top-selling medicinal or
food supplement products in the United States and
Europe [1-3]. Recent studies have shown that treatment
with specific Echinacea  extracts activates macrophages,
natural killer cells, or other immune cells [4-6]. Echinacea
extracts have also been reported to stimulate the secretion
of cytokines such as tumor necrosis factor-alpha, inter-
feron, interleukin-1 and interleukin-6 [7-10]. In vivo stud-
ies have shown that treatment with Echinacea extracts can
increase the number of white blood cells in the circulatory
system [11], enhance phagocytosis [12], and trigger the
alternate complementary pathway [13]. Echinacea extracts
have been marketed as possible immune stimulators or
enhancers worldwide. These phyto-extracts have been
actively evaluated in various clinical studies as candidate
therapeutics or preventive remedies for upper respiratory
tract infections, common cold, urogenital infection and
wound healing [14-19]. However, the results from various
studies on the efficacy of Echinacea extracts for prevention
of experimental colds or common cold have been contro-
versial [16-20]. The most recent study, as a meta-analysis
for evaluating the effect of Echinacea, addressed again on
the potential use and problems of Echinacea as remedy for
common cold/flu [20,21].
Dendritic cells (DCs) are involved in a spectrum of
immune cell functions, including antigen-presentation
and phagocytic activity, and play important roles in both
innate and adaptive immunities [22]. DCs can capture
and transfer molecular or cellular information from the
body's outside or interface environment to cells of differ-
ent immune systems. These cells are not only critical for
the induction of primary immune responses but are also
involved in the regulation of T cell-mediated immunity
[22]. Recently, a series of studies developed DC-based
immunotherapy or vaccine protocols designed to elicit
specific immunity against certain cancers [12,23,24]. Echi-
nacea plant extracts have been shown to have immune-
modulatory effects [3,11-13], and we recently reported on
the possible use of Echinacea purpurea (Ep) phytocom-
pounds as immune-modifiers for human DC activity [25].
Echinacea extracts have significant and specific modula-
tory effects on human DCs, but these effects are plant tis-
sue-specific, the bioactivity varying greatly between root
and shoot plus leaf (S+L) tissues. In this follow-up study,
we further investigated in detail the effect of a partially
purified and chemically defined Ep phytocompound mix-
ture on human DCs.
Recent gene expression profiling in DCs have shown that
DCs can actively process environmental signals and acti-
vate different transcriptional programs in response to dis-
tinct stimuli [26]. In this study, we used functional
genomics to analyze changes in gene expression in human
immature DCs in response to treatment with the butanol-
partitioned fraction (BF) of the S+L tissue extracts of E.
purpurea [BF/S+L/Ep] and cichoric acid (a major compo-
nent of this fraction) through Affymetrix gene chip micro-
array analyses. High-resolution 2-D gel electrophoresis,
MALDI-TOF mass spectrometry (MS), tandem MS-MS
analysis, and bio-informatics database systems were sub-
sequently employed for proteomics studies in parallel
with the genomics studies. Results from these analyses
and cell-based bioactivity-guide assays suggest that groups
of differentially expressed genes, specific functional genes,
and the associated molecular signaling networks can be
employed as potential targets for future systematic studies
of the response of human DC systems, as a response to tra-
ditional herbal medicine formulations or their derived
phytocompounds.
Results
Effect of [BF/S+L/Ep] extract on expression of cell surface 
markers in human iDCs
Flow cytometry revealed that [BF/S+L/Ep] enhanced the
expression of CD83, a key marker for DC maturation in
iDCs, as compared with vehicle (0.1% DMSO) treatment
(Figure 1) and the percentage of CD83+ expressing cells
increased, from 20% to 45% with 10, 50 and 100 μg/ml
[BF/S+L/Ep]. However, treatment with the ethyl acetate
(EA) fraction of the S+L extract at 1, 10, or 50 μg/ml sig-
nificantly decreased the percentage of CD83+ expressing
cells from 20% to 0% (Figure 1). The observed effects were
not caused by cellular mechanisms related to cytotoxicity,
since MTT assay results indicated that treatment with EA
Specific bioactivities of three subfractions of stem and leaf  (S+L) extracts of E. purpurea in human immature dendritic  cells (iDC) Figure 1
Specific bioactivities of three subfractions of stem 
and leaf (S+L) extracts of E. purpurea in human 
immature dendritic cells (iDC). iDCs were treated for 
24 h with the S+L tissue extracts and the derived ethyl ace-
tate (EA), butanol (BuOH), or water fractions. Test cells 
were subsequently analyzed for cell-surface marker CD83 
expression by flow cytometry.
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(1 to 50 μg/ml) or [BF/S+L/Ep] (1 to 100 μg/ml) showed
98% to 125% cell viability as compared to vehicle treat-
ment (data not shown). Thus, the [BF/S+L/Ep] fraction
but not the EA fraction could enhance the maturation of
iDCs. To reach this conclusion, it is essential for us to rule
out the possibility that lipopolysaccharide (LPS), as a bac-
terial endotoxin contamination of the [BF/S+L/Ep] extract
preparations, might have contributed to the observed
results in the present CD83 assay and the subsequent
functional genomics and proteomics studies. By using a
LAL assay (see Methods), we have obtained a firm nega-
tive results (<0.125 EU/ml) on the presence of a signifi-
cant level of LPS in our [BF/S+L/Ep] extract fraction.
EchinaforceTM, a standardized commercial product from
Swiss registered E. purpurea (L.) Moench fresh plant tinc-
ture, was reported to contain an endotoxin level of <0.5
EU/ml, and this tincture was used in a randomized dou-
ble-blind clinical study [27]. In comparison, our plant
extract fraction, [BF/S+L/Ep], was detected to contain a
considerably lower level of possible endotoxin contami-
nation (<0.125 EU/ml). We therefore are confident that a
LPS effect on various bioactivities can virtually be ruled
out from our present studies.
Compound identification and fingerprint analysis of the 
bioactive [BF/S+L/Ep] fraction
The overall metabolite profile of [BF/S+L/Ep] of E. purpu-
rea was analyzed using RP-HPLC, detected at A330 or A254
(Figure 2A). Seven phytocompounds (1-7)  namely
hypoxanthine (1), chlorogenic acid (2), caffeic acid (3),
cichoric acid (4), quercetin 3-O-rhamnosyl-(1→6)-galac-
toside (5), kaempferol 3-O-rhamnosyl-(1→6)-galactoside
(6), and rutin (7) were identified by a combination of
chomatography on RP-18 silica gel, Sephadex gel, and
C18 RP-HPLC. Structures were elucidated by 1H-nuclear
magnetic resonance (NMR), 13C-NMR and MS, and con-
firmed with previous data [28-34]. LC/electrospray ioni-
zation-MS was further employed to establish the chemical
fingerprints with two index compounds of [BF/S+L/Ep].
The RP-HPLC chromatogram detected at 330 nm of [BF/
S+L/Ep] was shown in Figure 2B (a) and the mass spectra
of the specific compounds were further characterized by
using their pseudo molecular weight at m/z 497 [M + Na]+,
TR = 36.8 min, compound 4, Figure 2B (b); and m/z 611
[M + H]+, TR = 40.3 min, compound 7, Figure 2B (c). These
result demonstrate that compounds 4 and 7 in [BF/S+L/
Ep] can be readily identified by comparing their corre-
sponding peaks (retention time) and MS data.
The levels of cichoric acid (4) and rutin (7) were quantita-
tively determined for use as candidate index compounds
for the [BF/S+L/Ep] fraction. Standard calibration curves
(peak area versus concentrations) prepared for cichoric
acid and rutin ranged from 0.125 to 1 mg/ml. Absorbance
of the compounds at 330 nm varied linearly within this
range. The amount of cichoric acid and rutin were deter-
mined as 8.4% (w/w) and 22.3% (w/w), respectively, of
the dry weight of the [BF/S+L/Ep] fraction. Together, the
results show that this [BF/S+L/Ep] phytocompound mix-
ture was effectively standardized and defined with a spe-
cific metabolite profile containing several candidate index
compounds (Figure 2). The standardized [BF/S+L/Ep]
fraction was then systematically used in the following bio-
activity assays to evaluate its immune regulatory effects in
human iDCs.
Affymetrix DNA microarray analysis of differential gene 
expression patterns in human iDCs in response to 
treatment with [BF/S+L/Ep] or cichoric acid
For DNA microarray analysis, iDCs differentiated from
primary monocytes in vitro were incubated with [BF/S+L/
Ep] or cichoric acid for 4 or 24 h to characterize early- or
late-responsive genes. A total of nine oligo-DNA chips
were hybridized to determine the transcriptome profiles
in human iDCs. The array data was normalized for identi-
fying differentially expressed genes, clustering and anno-
tation. We selected 382 genes for clustering by gap statistic
analysis. Figure 3 shows a heat map of differential gene
expression patterns and a plot of the resultant 6 possible
gene clusters. The K-means clustering revealed that some
genes exhibited a consistent response, for example with
increased expression at both 4 h and 24 h after treatment
with [BF/S+L/Ep]. Alternatively, some genes highly
expressed at 4 h but not at 24 h after treatment, or at 24 h
but not at 4 h post-treatment, and these may reflect other
sets of specific and differential transient gene expression
patterns.
Approximately 119 genes were up-regulated by ≥ 2-fold
change in expression at 4 h post-treatment with [BF/S+L/
Ep], with 20 genes showing 11- to 31-fold change in
expression (Table 1A). About 20 genes were down-regu-
lated by > 2-fold change in expression at 4 h post-treat-
ment (Table 1A). Most notably, four up-regulated genes
(CCL2 [MCP1], CCL5 [RANTES], NF-κB activator and IL-
8), and two down-regulated genes, IFN-α16 and leukocyte
immunoglobulin-like receptor [LILRB3], are well known
to be involved in various key immune-modulatory activi-
ties. Changes in expression noted after 24 h treatment are
summarized in Table 1B. Treatment with cichoric acid, a
key principle component of the [BF/S+L/Ep] fraction, gave
a different expression profile in iDCs. A total of 81 genes
and 46 genes were up-regulated and down-regulated,
respectively, with 2-fold change in expression at 4 h post-
treatment (data not shown). The top 20 up- or down-reg-
ulated genes, with 2.6- to 18.0-fold increase or 0.23- to
0.45-fold decrease in expression at 4 h were chosen for
further analysis (Table 2A). At 24 h after treatment, 79
genes were up-regulated and 81 down-regulated with ≥ 2-
fold change in expression (data not shown). The top 20BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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Chemical fingerprints and candidate index compounds identified in the [BF/S+L/Ep] fraction of E. purpurea. (A) Metabolite pro- file at 330 and 254 nm and the structures of compounds 1-7 identified from [BF/S+L/Ep] Figure 2
Chemical fingerprints and candidate index compounds identified in the [BF/S+L/Ep] fraction of E. purpurea. (A) 
Metabolite profile at 330 and 254 nm and the structures of compounds 1-7 identified from [BF/S+L/Ep]. (B) RP-HPLC chroma-
togram of [BF/S+L/Ep] at 330 nm (a) analysis on ESI-MS to obtain m/z ratios of (b) m/z 497, and (c) m/z 611 for compounds 4 
and 7, respectively.
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Comparative analysis of differential gene expression patterns in immature dendritic cells treated with [BF/S+L/Ep] and specific  phytocompounds by K-means clustering analyses Figure 3
Comparative analysis of differential gene expression patterns in immature dendritic cells treated with [BF/
S+L/Ep] and specific phytocompounds by K-means clustering analyses. Analysis of test iDC samples (including vehi-
cle control [+DMSO only]) involved comparing the treatment values with untreated values (i.e., zero hour-treated). The left 
panel shows the heat map of the resulting clustered gene expression. The number of genes involved and the mean profile for 
each cluster is in the right panel. The mean profile was superimposed with error bars showing ± 1 standard error of the mean.BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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Table 1: Effect of [BF/S+L/Ep] on gene expression in human iDCs
Fold Change
Gene Name Common Name Accession No Treatment/Control
(From 31 to 11-fold)
(A) Up-regulated at 4 h post-treatment
EH-domain containing 1 EHD1 NM_006795 31.81
chemokine (C-C motif) ligand 2 CCL2 NM_002982 22.15
cryptochrome 1 (photolyase-like) CRY1 NM_004075 21.65
BCL-6 interacting corepressor BCOR NM_017745 21.62
tumor necrosis factor receptor superfamily, member 4 TNFRSF4 NM_003327 19.10
Xenopus prevents mitotic catastrophe 2 homolog XPMC2H NM_020385 17.54
basic transcription element binding protein 1 BTEB1 NM_001206 17.45
Janus kinase 2 (a protein tyrosine kinase) JAK2 NM_004972 16.40
wingless-type MMTV integration site family, member 5A WNT5A NM_003392 15.42
discs, large (Drosophila) homolog 1 DLG1 NM_004087 15.22
RAB35, member RAS oncogene family RAB35 NM_006861 14.79
hypothetical protein DKFZp564O0523 DKFZP564O0523 AL136619 14.17
triple functional domain (PTPRF interacting) TRIO NM_007118 14.12
zinc finger and BTB domain containing 1 ZBTB1 NM_014950 13.75
chemokine (C-C motif) ligand 5 CCL5 NM_002985 13.62
TRAF family member-associated NF-κB activator TANK BC003388 13.12
Interleukin 8 IL8 NM_000584 12.16
HSPCO34 protein LOC51668 NM_016126 11.37
suppression of tumorigenicity ST7 NM_013437 11.37
chemokine (C-X-C motif) ligand 2 CXCL2 NM_002089 10.77
Down-regulated at 4 h post-treatment (From 0.49 to 0.47-fold)
transducin (beta)-like 2 isoform 1 TBL2 NM_012453 0.50
decorin isoform a preproprotein DCN NM_001920 0.50
nucleolar protein family A, member 2 NOLA2 NM_017838 0.50
leukocyte immunoglobulin-like receptor LILRB3 NM_006864 0.50
calpain 3 isoform a CAPN3 NM_000070 0.49
interferon, alpha 16 IFNA16 NM_002173 0.49
chromosome 5 open reading frame 4 C5ORF4 NM_016348 0.49
tripartite motif-containing 45 TRIM45 NM_025188 0.49
A kinase (PRKA) anchor protein 7 isoform alpha AKAP7 NM_004842 0.49
carbonic anhydrase IV precursor CA4 NM_000717 0.49
uncoupling protein 3 isoform UCP3L UCP3 NM_003356 0.49
NICE-4 protein NICE-4 NM_014847 0.48
alpha 2 type V collagen preproprotein COL5A2 NM_000393 0.48
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin 
a3
SMARCA3 NM_003071 0.48
CD27-binding (Siva) protein isoform 1 SIVA NM_006427 0.48
prostate derived STE20-like kinase PSK PSK NM_016151 0.48
stanniocalcin 2 STC2 NM_003714 0.48
arginine-glutamic acid dipeptide (RE) repeats RERE NM_012102 0.48
stimulated by retinoic acid gene 6 FLJ12541 NM_022369 0.48
zinc finger protein 228 ZNF228 NM_013380 0.48
Fold Change
Gene Name Common Name Accession No Treatment/Control
(From 28 to 4.6-fold)
(B) Up-regulated at 24 h post-treatment
protein tyrosine phosphatase, non-receptor type 2 PTPN2 NM_002828 28.77
solute carrier family 26, member 4 SLC26A4 NM_000441 25.07
adaptor-related protein complex 4, sigma 1 subunit AP4S1 NM_007077 23.91
zinc finger protein RINZF RINZF NM_023929 15.88
calbindin 1, 28kDa CALB1 NM_004929 15.57
chromosome 9 open reading frame 10 C9ORF10 AF214738 12.75
secreted frizzled-related protein 1 SFRP1 NM_003012 10.17
cholinergic receptor, nicotinic, alpha polypeptide 5 CHRNA5 NM_000745 9.95
chorea acanthocytosis CHAC AB023203 9.91BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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up- or down-regulated genes, with 5.36- to 18.9-fold
increase or 0.13- to 0.37-fold decrease in expression at 24
h were chosen for further evaluation (Table 2B). As shown
in Table 3, among the groups of genes up- or down-regu-
lated by cichoric acid versus [BF/S+L/Ep] treatment for 24
h, an overlapping expression pattern was observed for 31
genes.
Putative signaling networks/pathways involved in the 
modulatory effect of [BF/S+L/Ep] on iDCs
To identify the possible putative signal transduction path-
ways, we analyzed, for 4 hr and 24 hr treatments, the top
20 up-regulated genes in human iDCs in response to treat-
ment with [BF/S+L/Ep] using TRANSPATH soft ware. Sig-
nal transduction pathways involving the MCP-1, IL-8,
CCL5, JAK2 and TRIO genes with ≥ 5-fold change in
expression on treatment (Table 1A) was identified. Signal-
ing pathway networking and gene function analyses led to
the hypothesis that treatment of iDC with [BF/S+L/Ep]
may activate the cyclic AMP and PKC pathways leading to
the regulation of a key down stream molecule, adenylate
cyclase 8 (AC8), in a Ca2+ dependent manner (Figure 4).
Construction of proteome maps and identification of 
differentially expressed proteins in human iDCs
Treatment of iDCs with 75 μg/ml [BF/S+L/Ep] or 50 μg/
ml cichoric acid resulted in differential expression of 43
proteins (Figures 5 and Table 4) identified by MALDI-
TOF-MS. These 43 proteins were further categorized by
function with use of the Swiss-Prot database. Most of the
proteins responding to [BF/S+L/Ep] (30.2%) were cell
growth- or maintenance-related proteins (Figure 6); these
included structural and cytoskeleton proteins such as
macrophage-capping protein, cofilin, profilin, F-actin
capping protein β subunit, and laminin A/C (Table 4).
Other major classes were energy pathway-related proteins
or metabolic enzymes (26.4%), proteins involved in pro-
tein metabolism or degradation (18.9%), and ion chan-
nel/transport proteins (13.2%). A small number were
related to signal transduction and cell communication
(5.7%), and others were associated with the regulation of
nucleotides and nucleic acid metabolism (5.7%). Some
proteins of interest include oxidative stress-related pro-
teins (superoxide dismutases [Mn, Cu and Zn], catalase
and peroxiredoxin 6) and cytoskeleton related proteins
(gelsolin, macrophage capping protein, actin related pro-
WAP four-disulfide core domain 8 WFDC8 AL133571 8.68
tripartite motif-containing 45 TRIM45 NM_025188 8.34
matrix metalloproteinase 2 MMP2 NM_004530 6.73
hook1 protein HOOK1 NM_015888 6.52
epidermal growth factor receptor pathway substrate 8-related protein 1 EPS8R1 AI343292 6.23
zinc finger protein (ZFD25) ZFD25 NM_016220 5.27
SUMO-1-specific protease SUSP1 NM_015571 5.02
nuclear respiratory factor 1 NRF1 NM_005011 4.97
phosphoribosyl pyrophosphate amidotransferase PPAT NM_002703 4.86
pleckstrin homology-like domain, family A, member 1 PHLDA1 NM_007350 4.79
vascular Rab-GAP/TBC-containing VRP NM_000993 4.61
Down-regulated at 24 h post-treatment (From 0.03 to 0.24-fold)
Chromosome 1 open reading fram 29 C1ORF29 NM_006820 0.04
protein (peptidyl-prolyl cis/trans isomerase) NIMA-interacting 1 PIN1 NM_006221 0.04
myxovirus resistance protein 1 MX1 NM_002462 0.09
sialoadhesin precursor SN NM_023068 0.10
interferon-induced protein with tetratricopeptide repeats 1 IFIT1 NM_001548 0.12
axonemal dynein heavy chain 7 DNAH7 NM_018897 0.13
ubiquitin specific protease 18 USP18 NM_017414 0.14
regulator of G-protein signaling 12 RGS12 NM_002926 0.14
interferon-induced, hepatitis C-associated microtubular aggregate IFI44 NM_006417 0.16
secreted protein of unknown function SPUF NM_013349 0.17
vacuolar protein sorting 41 (yeast homolog) isoform 1 VPS41 NM_014396 0.18
SP140 nuclear body protein SP140 NM_007237 0.19
interferon, alpha-inducible protein G1P2 NM_005101 0.19
interferon-induced protein with tetratricopeptide repeats 4 IFIT4 NM_001549 0.21
small inducible cytokine B11 precursor CXCL11 NM_005409 0.29
phospholipid scramblase 1 PLSCR1 NM_021105 0.22
viperin CIG5 NM_080657 0.22
muscle-specific beta 1 integrin binding protein MIBP NM_170678 0.23
translation initiation factor IF2 IF2 NM_015904 0.25
serine (or cysteine) proteinase inhibitor, clade A, member 1 SERPINA1 NM_000295 0.25
Top 20 genes up- or down-regulated in human immature DCs in response to treatment with (BF/S+L/Ep) fraction of Echinacea purpurea for 4 h (A) 
or 24 h (B) by fold change in expression.
Table 1: Effect of [BF/S+L/Ep] on gene expression in human iDCs (Continued)BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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Table 2: Effect of cichoric acid on gene expression in human iDCs
Fold Change
Gene Name Common Name Accession No Treatment/Control
(From 18 to 2.6-fold)
(A) Up-regulated at 4 h post-treatment
discs, large (Drosophila) homolog 1 DLG1 NM_004087 18.24
pre-B-cell leukemia transcription factor 2 PBX2 NM_002586 6.45
inhibitor of DNA binding 4, dominant negative helix-loop-helix protein ID4 NM_001546 4.22
contactin associated protein-like 2 CNTNAP2 NM_014141 4.00
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 6 (RNA helicase, 54 kDa) DDX6 NM_004397 3.74
guanine nucleotide binding protein (G protein), alpha inhibiting activity 
polypeptide 1
GNAI1 NM_002069 3.66
tropomodulin 3 (ubiquitous) TMOD3 NM_014547 3.60
tissue factor pathway inhibitor (lipoprotein-associated coagulation inhibitor) TFPI NM_006287 3.13
tolloid-like 1 TLL1 NM_012263 3.09
RAB3 GTPase-activating protein RAB3GAP XM_040048 3.08
histone 1, H2al HIST1H2AL NM_003511 3.07
solute carrier family 4, sodium bicarbonate cotransporter, member 7 SLC4A7 NM_003615 3.00
fibulin 1 FBLN1 NM_006486 2.97
cytochrome P450, family 2, subfamily C, polypeptide 8 CYP2C8 NM_030878 2.86
peptidyl-prolyl isomerase G (cyclophilin G) PPIG NM_004792 2.80
Nijmegen breakage syndrome 1 (nibrin) NBS1 AK001017 2.76
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8 kDa NDUFB2 NM_004546 2.71
cytosolic ovarian carcinoma antigen 1 COVA1 NM_006375 2.69
zinc finger protein 305 ZNF305 NM_014724 2.67
platelet-activating factor acetylhydrolase, isoform Ib, beta subunit 30 kDa PAFAH1B2 NM_002572 2.60
Down-regulated at 4 h post-treatment (From 0.23 to 0.45-fold)
glycerol kinase GK NM_000167 0.23
SMC4 structural maintenance of chromosomes 4-like 1 (yeast) SMC4L1 AL136877 0.31
ATPase, Ca+2 transporting, type 2C, member 1 ATP2C1 AB037768 0.36
megakaryocyte-associated tyrosine kinase MATK NM_002378 0.37
ubiquitin specific protease 24 USP24 XM_165973 0.37
SEC24 related gene family, member D (S. cerevisiae) SEC24D NM_014822 0.38
talin 1 TLN1 NM_006289 0.39
methionyl aminopeptidase 2 METAP2 NM_006838 0.39
protein kinase, cAMP-dependent, regulatory, type II, beta PRKAR2B NM_002736 0.42
endothelial differentiation, G-protein-coupled receptor, 2 EDG2 NM_001401 0.42
integrin, beta 8 ITGB8 NM_002214 0.42
uridine monophosphate synthetase UMPS NM_000373 0.42
ribosomal protein L13 RPL13 AA789278 0.43
DNA cross-link repair 1B DCLRE1B NM_022836 0.43
chloride channel, calcium activated, family member 2 CLCA2 NM_006536 0.43
caspase 2, apoptosis-related cysteine protease CASP2 NM_032982 0.44
apoptotic chromatin condensation inducer in the nucleus ACINUS NM_014977 0.45
peptidoglycan recognition protein-I-beta precursor PGLYRPIBETA NM_020393 0.45
Fold Change
Gene Name Common Name Accession No Treatment/Control
(From 18.9 to 5.4-fold)
(B) Up-regulated at 24 h post-treatment
Zinc finger protein 229 ZNF228 AC084239 18.93
adaptor-related protein complex 4, sigma 1 subunit AP4S1 NM_007077 14.10
chromosome 8 open reading frame 17 C8ORF17 NM_020237 12.13
DKFZP566K023 protein DKFZP566K023 NM_015485 11.07
glycine receptor, alpha 1 GLRA1 NM_000171 10.81
frizzled homolog 3 (Drosophila) FZD3 NM_017412 10.31
secreted frizzled-related protein 1 SFRP1 NM_003012 10.11
chorea acanthocytosis CHAC AB023203 9.56
actin, alpha, cardiac muscle ACTC NM_005159 9.51
tripartite motif-containing 45 TRIM45 NM_025188 8.26
phosphodiesterase 4D, cAMP-specific PDE4D AF012073 8.23BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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tein 3, coronin-1C, beta adducin, vimentin, WD-repeat
protein 1, T-complex protein 1 epsilon subunit, T-com-
plex protein 1- beta subunit, cofilin, F-actin capping pro-
tein beta subunit 2, actin-related protein 2/3 complex
subunit 2, profilin-1). These specific proteins may warrant
further evaluation because of their apparent roles in mod-
ulation of DC maturation and function.
Confirmation of up- or down-regulation of specific 
proteins
Western blot analysis was conducted to confirm some of
the up-regulated proteins observed from proteomic anal-
ysis. The expression of Mn-SOD (SOD2) was increased
2.65- to 1.99-fold with [BF/S+L/Ep] and 2.35- and 1.67-
fold with cichoric acid treatment at 12 and 24 h, respec-
tively, as compared with vehicle controls, which is consist-
ent with results from 2-D gel electrophoresis (Figure 7,
Table 4). The levels of cofilin determined by 2-D gel elec-
trophoresis (Figure 8A) were slightly decreased, by 0.75-
and 0.84-fold, with [BF/S+L/Ep] and greatly decreased, by
0.09- and 0.42-fold, with cichoric acid treatment at 12 or
24 h, respectively. Interestingly, confirmation by Western
blot analysis revealed only a 0.5- and 0.32-fold decrease in
cofilin level at 12 and 24 h with cichoric acid treatment
(Figure 8B). Both assay systems revealed reduced effect of
[BF/S+L/Ep] on cofilin expression in iDCs (0.75- and
0.84-fold, respectively) (Figure 8A Vs 8B). Nevertheless,
these results confirmed our finding that the expression of
cofilin in iDCs can be substantially reduced by treatment
with cichoric acid and may be slightly inhibited by [BF/
S+L/Ep]. Rutin, another major index component of the
[BF/S+L/Ep], effectively inhibited the expression of cofi-
lin, by 0.4- and 0.6-fold at 12 and 24 h, respectively, in
iDCs (Figure 8B). Treatment with 100 ng/ml lipopolysac-
charide (LPS, used as a positive control) conferred an
approximately 0.5- to 0.4-fold decrease in cofilin expres-
sion as compared to controls (Figure 8B).
Discussion
Results of some clinical studies are controversial about the
effects of the traditional herbal medicine Echinacea
extracts [14-19], even though recent studies seemed to
provide some support for its possible beneficial effects for
treatment of the common cold [20,21]. In addition, stud-
ies from animal experiments have shown that alkamides
form Echinacea extracts may confer immune-modulatory
activities [35,36]. Among these different observations, we
believe it is important to evaluate systematically the spe-
cific and multiple effects of Echinacea phytocompounds
on human immune cells, at the cellular and molecular
v-Ki-ras2 Kirsten rat sarcoma 2 viral oncogene homolog KRAS2 NM_004985 7.79
absent in melanoma 1-like AIM1L NM_017977 6.79
protein phosphatase 2, regulatory subunit B, beta isoform PPP2R2B NM_004576 6.75
integral membrane protein 2A ITM2A AL021786 6.43
cannabinoid receptor 1 (brain) CNR1 U73304 6.09
cholinergic receptor, nicotinic, alpha polypeptide 5 CHRNA5 NM_000745 6.02
SMC5 structural maintenance of chromosomes 5-like 1 (yeast) SMC5L1 NM_015110 5.78
protein kinase, cAMP-dependent, regulatory, type I, beta PRKAR1B AL833563 5.77
ATP-binding cassette, sub-family A (ABC1), member 1 ABCA1 AF285167 5.36
Down-regulated at 24 h post-treatment (From 0.13 to 0.37-fold)
interferon-inducible protein p78 (mouse) MX1 NM_002462 0.13
interferon-induced protein 44 IFI44 NM_006417 0.16
interferon, alpha-inducible protein (clone IFI-15K) G1P2 NM_005101 0.20
protein kinase, interferon-inducible double stranded RNA dependent PRKR NM_002759 0.21
2'-5'-oligoadenylate synthetase 2, 69/71 kDa OAS2 NM_016817 0.24
BCL2-like 11 (apoptosis facilitator) BCL2L11 NM_006538 0.28
methionyl aminopeptidase 2 METAP2 NM_006838 0.28
signal transducer and activator of transcription 1 (91 kDa) STAT1 NM_007315 0.29
myxovirus (influenza virus) resistance 2 (mouse) MX2 NM_002463 0.30
SP110 nuclear body protein SP110 AF280094 0.30
sialoadhesin SN NM_023068 0.30
mitochondrial ribosomal protein S14 MRPS14 NM_022100 0.31
similar to S. cerevisiae SSM4 TEB4 NM_005885 0.31
XIAP associated factor-1 HSXIAPAF1 NM_017523 0.33
SP110 nuclear body protein SP110 NM_004509 0.35
retinitis pigmentosa 2 (X-linked recessive) RP2 NM_006915 0.36
zinc finger protein 83 (HPF1) ZNF83 NM_018300 0.36
zinc finger antiviral protein ZAP NM_020119 0.36
TIA1 cytotoxic granule-associated RNA binding protein TIA1 NM_022173 0.38
RAN binding protein 9 RANBP9 NM_005493 0.38
Top 20 genes up- or down-regulated in human immature DCs in response to treatment with cichoric acid (50 g/ml) of Echinacea purpurea for 4 h 
(A) by fold change in expression.
Table 2: Effect of cichoric acid on gene expression in human iDCs (Continued)BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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levels. Previously, we reported that un-fractionated, crude
extracts of E. purpurea plant tissues could affect specific
cell-surface markers of human DCs [25], which suggests
the potential of using human DCs as an experimental sys-
tem for in-depth study of the effect of Echinacea phyto-
compounds on important human immune cell systems.
In the current study, we evaluated and characterized the
possible immune-modulatory effect(s) of phytocom-
pounds from E. purpurea, as an organic solvent-fraction-
ated phytocompound mixture or a single major
component (cichoric acid), on human DCs. Using tran-
scriptome and proteome experimental approaches, we
analyzed the global and differential gene expression pat-
terns at the mRNA and protein levels in human mono-
cyte-derived iDCs treated with test phytocompounds.
Previous studies have demonstrated that DCs play impor-
tant roles in initiating and regulating innate as well as
adaptive immunities [22]. Under normal conditions, DCs
are present in most tissues in a relatively immature state,
but with inflammation, irritation or danger signals from
foreign antigens or environment, iDCs undergo rapid
changes and initiate a cascade of activities to defend the
body system. The phenotypic and functional characteris-
tics of DCs are intimately and dynamically linked to their
stage of differentiation and maturation [37]. Human DCs
Table 3: Genes showing overlapping up- or down-regulation in iDCs after treatment with [BF/S+L/Ep] or cichoric acid
Genes up-regulated Genebank Fold Change in Treatment with [BF/
S+L/Ep] (From 23.9 to 2.7-fold)
Fold Change in Treatment with 
Cichoric Acid (From 14 to 3.1-fold)
adaptor-related protein complex 4 NM_007077 23.91 14.10
secreted frizzled-related protein 1 NM_003012 10.17 10.11
cholinergic receptor NM_000745 9.95 6.02
chorea acanthocytosis AB023203 9.91 9.56
tripartite motif-containing 45 NM_025188 8.34 8.26
zinc finger protein (ZFD25) NM_016220 5.27 5.35
SUMO-1-specific protease NM_015571 5.02 4.56
nuclear respiratory factor 1 NM_005011 4.97 3.39
pleckstrin homology-like domain NM_007350 4.79 3.36
protein phosphatase 2 NM_004576 4.56 6.75
chromosome 19 open reading frame 2 NM_003796 3.91 3.27
SMC5 structural maintenance of 
chromosomes 5-like 1 (yeast)
NM_015110 3.87 5.78
myeloid/lymphoid or mixed-lineage 
leukemia
NM_004641 3.70 5.34
aryl hydrocarbon receptor interacting 
protein-like 1
NM_014336 3.60 3.70
left-right determination, factor B NM_020997 3.53 4.14
ATP-binding cassette, sub-family A NM_005502 3.35 5.36
RBP1-like protein NM_016374 3.07 3.26
solute carrier family 26, member 10 NM_133489 2.89 3.05
insulin induced gene 1 NM_005542 2.87 3.12
ceroid-lipofuscinosis, neuronal 8 NM_018941 2.72 3.10
Genes down-regulated Gene bank (From 0.08 to 0.38-fold) (From 0.13 to 0.4-fold)
Interferon-inducible protein p78 
(mouse)
NM_002462 0.09 0.13
Interferon-inducible protein 44 NM_006417 0.16 0.16
Interferon, alpha-inducible protein 
(clone IFI-15K)
NM_005101 0.19 0.20
Mitochondrial ribosomal protein S14 NM_022100 0.27 0.31
2'-5'-oligoadanylate synthetase 2, 69/
71 kDa
NM_016817 0.27 0.24
Myxovirus (influenza virus) resistance 
2 (mouse)
NM_002463 0.29 0.30
XIAP associated factor-1 NM_017523 0.30 0.33
SP110 nuclear body protein NM_080424 0.33 0.35
Signal transducer and activator of 
transcription 1, (91 kDa)
NM_007315 0.33 0.29
zinc finger antiviral protein NM_020119 0.34 0.36
Solute carrier family 35 NM_012243 0.36 0.38
Human immature DCs were treated for 24 h with test samples and assayed for differential gene expression.BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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have been recently recognized as a promising cell system
for ex vivo/in vitro tissue culture manipulations for poten-
tial clinical application as tumor vaccines for cancer ther-
apy [23].
Initially, we used the expression of a highly specific cell-
surface and DC maturation maker, CD83, as a key indica-
tor for assessing possible immune modulatory effects of
Echinacea extracts on human DCs. The butanol fraction
[BF/S+L/Ep] significantly stimulated but the ethylacetate
(EA) fraction greatly inhibited CD83 expression in iDCs,
which suggests a possible immune modulatory effect of
[BF/S+L/Ep] on the maturation of iDCs and that different
sub-fractions of the phytocompound mixtures/herbal
extracts could confer different or even opposite biological
activities. These findings thus strongly suggest the urgent
need for a clear, specific and stringent definition(s) of the
extraction, fractionation and plant-tissue usage of the
medicinal herb preparations and the derived phytocom-
pounds for both laboratory experimental studies and
commercial applications. The lack of such definition and
information has already raised public concern.
Since our results on CD83 protein expression suggested
that the [BF/S+L/Ep] may stimulate the maturation of
iDCs, we subjected this butanol fraction to HPLC analysis
to characterize the major components and some possible
active compounds. We identified seven specific phyto-
compounds, namely hypoxanthine, caffeic acid, chloro-
genic acid, cichoric acid, rutin, quercetin 3-O-rhamnosyl-
(1→6)-galactoside, and kaempferol 3-O-rhamnosyl-
(1→6)-galactoside from the [BF/S+L/Ep] fraction. The
content of two major compounds cichoric acid (4) and
rutin (7) were quantified, and this data could be used as
chemical fingerprints and index compounds for future
study and standardization of the bioactive [BF/S+L/Ep]
fraction of E. purpurea. Potential future application of the
[BF/S+L/Ep] fraction for use as remedy, nutraceutical or
food supplement would have to wait until future studies
are carried out with the considerations of appropriate dos-
age, bio-activity and defined immuno-modulatory func-
tions to be assayed under in vivo conditions.
Use of the Affymetrix microarray analysis revealed approx-
imately 10% of the whole human genome effectively
expressed in DCs (data not shown). A total of 400 genes
(≈18% of the expressed genes) were differentially or spe-
cifically regulated during the differentiation or matura-
tion of iDCs. The top 20 genes with significantly up
regulated expression (> 3-fold change) at 4 h post-treat-
ment with [BF/S+L/Ep] include some important early-
responsive chemokine genes such as CCL2, CCL5 and IL-
8, previously reported to play important roles in inflam-
matory responses [38]. Although treatment with cichoric
acid did not affect CD83 expression, as was observed for
[BF/S+L/Ep], it nonetheless up-regulated a similar subset
of early response genes. Additional analysis of genes with
overlapping expression on treatment with both [BF/S+L/
Ep] and cichoric acid revealed that some of the interferon-
inducible proteins, including IFI44, IFI78 (Table 3), IFIT1
and the interferon alpha-inducible protein (Table 1B),
were all down-regulated at 24 h post-treatment. Thus, sev-
eral key chemokine genes are likely involved in the early
response to treatment with specific Echinacea phytocom-
pounds, and another set of interferon-inducible genes
belong to the group of late-responsive genes. We also per-
Bioinformatics analysis of candidate molecular signaling net- works of genes differentially expressed in [BF/S+L/Ep]- treated iDCs Figure 4
Bioinformatics analysis of candidate molecular sign-
aling networks of genes differentially expressed in 
[BF/S+L/Ep]-treated iDCs. The TRANSPATH Profes-
sional 7.1 database was searched to assess the possible sign-
aling pathways, networks or potential interactions among the 
responsive genes/target molecules in iDCs treated with [BF/
S+L/Ep]. The 20 genes that were up- or down-regulated at 
least 5-fold over controls were analyzed. Specifically, connec-
tions (hits) within 7 genes were employed as the parameter 
for the current search. Two postulated key molecules/path-
ways, Adenylate cyclase (AC8) and calmudulin (CaM), 
responsive to [BF/S+L/Ep] treatment were indicated indi-
cated by thick and thin arrows, respectively.B
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Table 4: Up- or down-regulation of proteins in human iDCs in response to treatment with [BF/S+L/Ep] or cichoric acid
Protein Name Protein Expression Ratio: Phytocompound Treated/Control 
(in 0.1% DMSO, Untreated)
Accession Number 
(SwissProt Data Base)
[BF/S+L/Ep] (75 ug/ml) Cichoric Acid (50 ug/ml)
12 h 24 h 12 h 24 h
Up-regulation in protein expression
Gelsolin 1.12 1.1 2.37 5.09 P06396
Macrophage capping protein 1.39 1.13 1.31 1.34 P40121
Actin-related protein 3 0.97 1.04 1 1.23 P61158
Coronin-1C 2.55 0.71 1.74 1.1 Q9ULV4
Beta adducing 1.1 1.49 1.34 1.69 P35612
Rho GDP-dissociation inhibitor 1 0.94 1.16 0.83 1.49 P52565
Rab GDP dissociation inhibitor beta 0.9 1.37 0.88 1.46 P50395
T-complex protein 1, epsilon subunit 1.29 1.03 1.17 1.44 P48643
Serum albumin [Precursor] 1.24 1.1 1.23 0.87 P02768
Vimentin 2.44 0.77 1.1 0.7 P08670
Protein disulfide-isomerase A3 [Precursor] 1.09 1.21 0.93 1.03 P30101
Carbonic anhydrase II 1.76 1.16 1.32 1.01 P00918
Catalase 1.14 1.21 1.28 1 P04040
Superoxide dismutase [Mn], mitochondrial 1.72 1.23 1.09 0.84 P04179
Peroxiredoxin 6 1 1.13 1.1 1.31 P30041
Biliverdin reductase A [Precursor] 1.21 1.05 1.32 1.27 P53004
Poly(rC)-binding protein 1 0.87 1 0.79 1.31 Q15365
WD-repeat protein 1 1.54 1.17 1.74 1.47 O75083
TFIIH basal transcription factor complex helicase subunit 0.88 1.06 0.86 1.36 P18074
Chloride intracellular channel protein 1 0.98 1.04 0.94 1.32 O00299
Potassium voltage-gated channel subfamily H member 5 0.89 1.07 1.14 1.68 Q8NCM2
Down-regulation in protein expression
Cofilin, non-muscle isoform 0.75 0.84 0.09 0.42 P23528
F-actin capping protein beta subunit 0.99 1.09 0.87 1.23 P47756
Actin-related protein 2/3 complex subunit 2 0.83 0.53 0.94 0.58 O15144
Profilin-1 0.84 0.76 0.6 0.51 P07737
Lamin A/C 0.81 0.69 0.45 0.76 P02545
Phosphoglycerate mutase 1 1.3 0.83 0.89 1.76 P18669
Superoxide dismutase [Cu-Zn] 0.84 0.99 0.78 1.48 P00441
Dihydrolipoyl dehydrogenase, mitochondrial [Precursor] 0.97 0.61 1.12 0.82 P09622
Galactose mutarotase 1.08 1.05 1.32 1.46 Q96C23
Delta3, 5-delta2, 4-dienoyl-CoA isomerase, mitochondrial 
[Precursor]
1.24 0.84 1.23 0.22 Q13011
Dihydropyrimidinase related protein-2 0.96 1.22 0.77 1.74 Q16555
26S proteasome non-ATPase regulatory subunit 13 0.94 1.32 0.95 1.42 Q9UNM6
60S acidic ribosomal protein P0 1.07 1.02 0.7 1.13 P05388
Heterogeneous nuclear ribonucleoprotein H 1 0.7 0.74 0.52 P31943BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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formed gene-clustering analysis to classify the gene
expression patterns in human iDCs. A total of 382 genes
were grouped into six clustering sets on the basis of their
expression in response to [BF/S+L/Ep] (Figure 3). In con-
trast, cichoric acid and vehicle treatment produced no
clustering differences, which suggests the lack of a multi-
domain or substantial effect of cichoric acid on most
expressed genes in iDCs.
We have identified a hypothetical signaling network
involving [BF/S+L/Ep]-induced early response genes such
as CCL2 (MCP-1), IL-8, CCL5, JAK2 and TRIO (Figure 4).
This signaling network revealed possible activation of
cAMP and PKC pathways leading to the regulation of AC8
through a Ca2+ receptor, calmodulin. Previous studies
have demonstrated that activation of cAMP induces DC
maturation and migration [39]. PKC plays an important
role in DC differentiation and antigen presenting function
[40]. In addition, Ca2+ dependent pathways have been
shown to regulate DC maturation and migration [41].
Our results on increased expression of CD83 maturation
marker coupled with candidate signal transduction path-
ways strongly suggest that [BF/S+L/Ep] may enhance the
iDC maturation and function, which warrants further sys-
tematic investigation.
2-D gel electrophoresis revealed 100 of the 1,300 detecta-
ble protein spots (≈7.7%) affected in iDCs after 12- or 24-
h treatment with [BF/S+L/Ep]. We suggest that this 7.7%
change in iDC protein levels may reflect a marked change
in protein expression, since the other cell types we have
studied in parallel (e.g., primary T-cells) showed only a
3% to 5% change (data not shown). We observed signifi-
cant up-regulation of antioxidant defense enzymes such
Differential expression pattern of proteins in iDCs treated with [BF/S+L/Ep] and derived phytocompounds Figure 5
Differential expression pattern of proteins in iDCs treated with [BF/S+L/Ep] and derived phytocompounds. 
Human iDCs in culture were treated with 0.1% DMSO (vehicle control), [BF/S+L/Ep] (75 μg/ml) and cichoric acid (50 μg/ml) 
for 12 or 24 h. Aliquots of equal amounts of solubilized total proteins from various test cell samples were analyzed by 2-D gel 
electrophoresis and MALDI-TOF-MS. Approximately 1,300 protein spots were detected in iDCs. Seventy gels were used for 
the present study, and highly similar results were obtained from three independent experiments, unless indicated otherwise.BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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as Mn-SOD, catalase and peroxiredoxin 6 in iDCs in
response to [BF/S+L/Ep] and cichoric acid. Endogenous
antioxidants have been reported to play key role in den-
dritic cell survival, and ability to induce T cell activation
and regulate the polarity of immune responses [42,43].
Several cytoskeletal and actin-binding proteins (Table 4)
were significantly up-regulated in [BF/S+L/Ep] or cichoric
acid treated iDCs. In DC, the changes in actin cytoskeleton
components are essential for the formation of its charac-
teristic dendrites and veils, as well as an immunological
synapse necessary for antigen presentation [44]. In addi-
tion, actin cytoskeleton rearrangement is important for
the motility and migration of cells and may influence the
migration of DC to lymph nodes during their maturation
[45]. Results from 2-D gel electrophoresis (Figures 7A and
8A) and Western blot analyses (Figures 7B and 8B) con-
firmed in general the trend of changes in differential
expression of Mn-SOD and cofilin. We therefore hypoth-
esize that a specific group of phytocompounds in Echina-
cea  may turn on the antioxidant defense system and
regulate the rearrangement of cytoskeleton, which in turn
may contribute to the positive enhancement of the
immunemodulatory activities of DCs.
The present study has identified a pool of known or
unknown genes associated with the differential expres-
sion of a spectrum of cytokines and chemokines and other
immune cell activities in response to treatment with Echi-
nacea compounds in DCs (Tables 1 to 4, and Figure 3). In
addition, changes in level of molecules related to cell
adhesion, immune-response and antigen presentation
were observed in this human DC model, providing candi-
date target genes/proteins for future cross-talk studies of
the biology of human DCs. These differentially expressed
genes and proposed candidate signaling pathways/net-
works obtained via bioinformatics approaches have pro-
vided us with useful potential clues and molecular targets
for future studies of molecular mechanisms underlying
specific immune modulatory effect(s) of important
medicinal herb Echinacea purpurea and derived phytocom-
pounds in iDCs.
Conclusion
Since dendritic cells are well characterized and recognized
as potent antigen presenting cells and have been shown to
play critical roles in both innate and adaptive immunities,
we have employed human DCs for functional genomics
studies to evaluate possible immuno-modulatory effects
Grouping of the identified human iDC proteins expressed in response to treatment with [BF/S+L/Ep], according to their  known cellular or biochemical functions Figure 6
Grouping of the identified human iDC proteins expressed in response to treatment with [BF/S+L/Ep], accord-
ing to their known cellular or biochemical functions. Assignment of biochemical functions of each protein involved with 
the use of information from the Swiss-Prot database at the ExPASY Molecular Biology Server http://www.expasy.org.
Transport
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Confirmation of the 2-D gel proteomic results on up-regulation of Mn-SOD protein expression with Western blot analysis Figure 7
Confirmation of the 2-D gel proteomic results on up-regulation of Mn-SOD protein expression with Western 
blot analysis. (A) Differential expression of Mn-SOD protein in iDCs treated with [BF/S+L/Ep] (75 μg/ml), cichoric acid (50 
μg/ml) or vehicle control, at both 12 and 24 h post-treatment, as revealed by 2-D gel electrophoresis, SYPRO Ruby dye stain-
ing, and quantification by PDQuest analysis. The arrows indicate the Mn-SOD protein spots detected in different treatments. 
The expression ratio compared to control gel is shown in black. (B) Western blot analysis of expression of Mn-SOD and actin 
in human iDCs treated with phytocompounds. Total cellular proteins were extracted and separated by 10% SDS-PAGE, and 
Western blot analysis performed with anti-Mn-SOD or anti-actin antibodies. Actin was used as a sample-loading control. Simi-
lar results were obtained from three independent experiments.
(A)
1
1
2.65 2.35
1.99 1.67
1
1
1.09 1.01
0.86 0.77
12h*:    1            2.43         2.33
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Confirmation of the 2-D gel proteomic results on down-regulation of cofilin protein expression with Western blot analysis Figure 8
Confirmation of the 2-D gel proteomic results on down-regulation of cofilin protein expression with Western 
blot analysis. (A) Differential expression of cofilin in human iDCs treated with [BF/S+L/Ep] (75 μg/ml), cichoric acid (50 μg/
ml) or vehicle control, at 12 and 24 h treatment, as revealed by 2-D gel electrophoresis. (B) Western blot analysis of expres-
sion of cofilin in human iDCs. Other experimental details are the same as described in Figure 7. Similar trends were observed 
in three independent experiments.
(A)
(B)BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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of specific phytocompound mixtures from a popular
medicinal herb extract, Echinacea purpurea. Specific and
differential gene expression patterns were detected in
time-course experiments of iDCs treated with the bioac-
tive phytocompound fraction ([BF/S+L/Ep]) and its major
index compound (cichoric acid). Transcritome analyses
showed significant up regulation of specific chemokine
and cytokine genes, including CXCL2, CCL5, CCL2, IL-8,
IL-1β and IL-18, within 4 h after [BF/S+L/Ep] treatment of
iDCs. Bioinformatics studies suggested that a key molecu-
lar signaling network involving a number of the detected
immune-modifier genes may lead to the activation of a
downstream adenylate cyclase 8 activities, contributing to
the observed cellular and molecular activities in test cells.
Subsequent proteomic studies further showed that expres-
sion of specific antioxidation and cytoskeletal proteins,
known to play important cellular physiological roles in
DCs, are increased in cichoric acid or [BF/S+L/Ep]-treated
cells. Based on these results, we conclude from this study
that specific phytocompound mixtures present as major
or active components in the test traditional herb may con-
fer defined and significant immuno-modulatory effects
on specific immune cell types. The candidate target mole-
cules and molecular signaling mechanisms identified
from this and previous study [25] provide us with useful
information and hypothesis for future studies on charac-
terization of human DCs in response to treatment with
medicinal phytocompounds at the transcriptome and
proteome levels.
Methods
Plant materials and crude extract preparations
E. purpurea plants at flowering stage were harvested from
a reputable organic farm in Puli, Nantou County, Taiwan.
Stem and leaf (S+L) tissues of fresh plants were extracted
at room temperature by imbibition with 70% aqueous
ethanol as previously reported [25]. The total 70% eth-
anolic extracts were concentrated (1 L) and successively
partitioned with ethyl acetate (1 L × 3 times) and n-buta-
nol (1 L × 3 times) to yield three sub-fractions, designated
as the EA, BuOH and Water fractions. The percentage of
yield for the three fractions was calculated as 10.3%,
7.23%, and 77.2%, respectively, of the 70% ethanolic
extracts in dry weight.
Generation of human dendritic cells
Monocyte-derived dendritic cells were generated from
peripheral blood mononuclear cells (PBMCs) isolated
from healthy volunteers blood samples as described pre-
viously [25]. Briefly, CD14+ monocytes were isolated by
passing the PBMCs through a magnetic cell separation sys-
tem (Miltenyi Biotec, Germany). CD14+  cells at 95%
purity were cultured for 7 days in AIM-V medium in the
presence of GM-CSF (1000 U/ml) and IL-4 (500 U/ml) to
obtain immature dendritic cells (iDCs).
Flow cytometry
At 24 h after treatment with E. purpurea crude extract, the
S+L extract, or the three subfractions, iDCs were harvested
and analyzed by immunofluorescence staining. Mono-
clonal antibodies labeled with fluorescent dyes i.e.,
HLADR-FITC, CD14-PE, CD32-PE, and CD83-FITC from
Immunotech (Fullerton, CA) and CD86-FITC from
Pharmingen (Fullerton, CA) were used. After incubation
with specific antibodies at 4°C for 30 min, cells were
washed twice with PBS and fixed with 1% paraformalde-
hyde, and subjected to analysis using a Coulter EPICS XL
flow cytometer (Beckman/Coulter, Durham, NC).
Cell viability assay
Human iDCs (4 × 105 cells/ml) were incubated with 0.1%
DMSO (vehicle control), test plant extract or derived phy-
tochemicals in basal medium in 96-well plates for 24 h in
a 5% CO2 incubator. All treatments were performed in
triplicate. Viability of iDCs was determined by MTT assay,
and percentage cell viability was calculated as previously
described [25]. The derived plant extracts from E. purpurea
were examined by a Limulus Amebocyte Lysate (LAL) test
(E-TOXATEâ Kits, Sigma, MO, USA) for detection of pos-
sible endotoxin (LPS) contamination before bioactivity
assays.
Phytocompound isolation
The BuOH fraction of the S+L tissues of E. purpurea, desig-
nated as [BF/S+L/Ep] hereafter, was subjected to choma-
tography on RP-18 silica gel with the H2O/MeOH solvent
system to yield four fractions. Fraction 1 was further puri-
fied by filtration though a Sephadex LH-20 (Amersham
Pharmacia Biotech) column with a H2O/MeOH gradient
solvent system to yield three sub-fractions. RP-18 high-
performance liquid chromatography (HPLC) column
(Phenomenex Luna, 5 μm C18, 250 × 10 mm) with a sol-
vent system, 0.05% TFA/H2O (solvent A) and 0.05% TFA/
MeOH (solvent B) and gradient profile (5-5% for 0 to 5
min, 5-20% for 5-30 min, and 20-50% for 30-60 min)
was used for isolation of single compounds. Quantifica-
tion of the index compounds in the active [BF/S+L/Ep]
fraction involved HPLC. The peak areas corresponding to
the content of candidate compounds of a known concen-
tration of the active fraction were calculated on the basis
of a standard calibration curve of the individual index
compounds. The HPLC profile and the relative content of
the index compounds were routinely used for quality con-
trol.
Chemical fingerprinting of the active [BF/S+L/Ep] fraction 
using LC/MS
LC/MS was employed to analyze the chemical fingerprint
of the [BF/S+L/Ep] fraction. LC/MS was carried out using
a ThermoFinnigan LCQ Advantage ion trap mass spec-
trometer equipped with an Agilent 1100 series liquidBMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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chromatographer, at the Metabolomics Core Facility of
the Agricultural Biotechnology Research Center,
Academia Sinica, Taiwan. Aliquot of a 5 μl sample of [BF/
S+L/Ep] (10 mg/ml) was injected and analyzed at a flow
rate of 0.2 ml/min. HPLC profiling involved an RP-18 col-
umn (Phenomenex Luna, 3 μm C18, 150 × 2 mm) and
eluted compounds detected by UV absorbance at 254 and
330 nm before MS analysis. The solvent gradient for
HPLC was 0.05% TFA/H2O (solvent A) and 0.05% TFA/
MeOH (solvent B): 5–5% for 0 to 5 min, 5–20% for 5–30
min, 20–45% for 30–40 min, and 45–50% for 40–50
min). Ionization involved the positive ion mode for all
analyses.
DNA microarray analysis of differential gene expression 
patterns
Total RNA was isolated by use of TRIzol® Reagent (Invit-
rogen) according to the manufacturer's instructions to
generate cRNA targets. A total of 7 μg of RNA from each
sample was used to synthesize the first-strand cDNA with
T7-Oligo (dT) primer and T7 RNA polymerase by in vitro
transcription reaction. The biotinylated cRNA products
were then cleaned according to the Affymetrix protocol.
Aliquots of 15 μg of total cRNA per sample were then
hybridized to the Affymetrix gene chip HG-U133A con-
taining approximately 22,283 probe sets following the
manufacturer's instructions. Images were obtained by
use of standard Affymetrix scanners. The cell intensities
and detection from the nine hybridized oligonucleotide
microarrays were derived by use of the Affymetrix Micro-
array Suite 5 (MAS 5.0) with default settings. Normaliza-
tion was by dChip with the PM-MM model-based
approach to obtain the expression indices for each probe
set [46]. The pool of the replicate arrays, CM-00h-1 and
CM-00h-2, was used as a baseline for normalization and
was applied to the calculation of log2 ratios, M, for the
test arrays. Comparative expression analysis of the two
arrays by the MAS 5.0 system reported a level of "no
change in gene expression pattern" of 98.0% (with a cor-
relation of 0.9916). This high reproducibility of results
indicates very high reliability and very low variation of
our experimental data obtained from the in-house
Affymetrix system. The gap statistic and K means analysis
were used to distinguish gene clusters as described previ-
ously [47,48]. The putative signal transduction pathways
were analyzed using TRANSPATH Professional 7.1 (BIO-
BASE Biological Databases, Germany). The microarray
data obtained from this study have been deposited to the
Gene Expression Omnibus database at NCBI (GEO;
http://www.ncbi.nlm.nih.gov/projects/geo/) under the
accession number GSE12259.
2-D gel electrophoresis and image analysis
Total cellular proteins of iDCs were extracted and pre-
pared in 0.3 ml of lysis buffer [7 M urea, 2 M thiourea, 4%
3,3-cholamidopropyl-dimethylammonio-1-propanesul-
fonate (CHAPS), 10% 1,4-dithiothreitol (DTT), 2% Phar-
malyte pH3-10] by vortexing for 1 h, and protein
supernatants were collected after ultracentrifugation at
55,000 rpm for 1 h. Protein concentrations were deter-
mined using Bio-Rad BCA protein assay kit (Bio-Rad, Her-
cules, CA). 2-D gel electrophoresis involved the
PROTEAN isoelectric focusing and electrophoresis system
(Bio-Rad, Hercules, CA) with modification [49]. Briefly,
550 μg of protein was diluted in 300 μl of rehydration
buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 2%
1,4-dithioerythitol, 0.13% Biolyte 5–8 (Bio-Rad) and
0.07% Biolyte 8–10 (Bio-Rad). Protein samples were
loaded onto IPG strips (Bio-Rad; 17 cm, pH 5–8) through
passive rehydration overnight. Proteins underwent electro
focusing analysis in slow-ramping mode with a final volt-
age of 8,000 V for a total of 25,000 Vh. Following a two-
step equilibration, IPG strips were processed by 10–16%
gradient SDS-PAGE and electrophoretic separation at 200
V. Gels were then fixed and stained with SYPRO-Ruby flu-
orescent stain (Molecular Probes; Eugene, OR) according
to the manufacturer's instructions. Stained gels were visu-
alized by a Typhoon scanner system (Amersham). Digital-
ized gel images were analyzed by 2-D PDQuest, V.T.O.
(Bio-Rad). Protein spots on gels were automatically
detected with use of the PDQuest system. The 2-D gel
images of iDCs proteins obtained with IPG strips (pH 5–
8) were matched separately, with each match set contain-
ing 9 images, with 3 images for control replicates. The
image with the highest number of spots was selected as
the master gel. Automatically detected images of protein
spots in test gels were then manually edited to include the
low intensity spots and corrected for spot artifacts. For the
match set containing images from pI 5–8, the spot volume
(intensity integrated over the spot area) was normalized
to the total volume of spots in the gel. Data were then
exported to Microsoft Excel.
Protein identification by MALDI-TOF-MS
Protein extraction was performed as previously described
[50]. Briefly, each gel spot was cut into small pieces with
a scalpel, washed with 700 μl of double distilled H2O, and
subjected to reduction reaction by DTT. Alkylation reac-
tion then carried out by adding 55 mM iodoacetamide for
1 h at room temperature in the dark. Gel spots were
washed with ammonium carbonate then acetonitrile. Gel
pieces were dried and then immersed in trypsin solution.
The in-gel digestion was performed at 37°C overnight.
Resulting tryptic peptides were extracted twice from the
test gel into 70% acetonitrile/5% HCOOH by sonication
then centrifugation. The combined supernatant was dried
under a Savant Speed Vac, and 6 μl of 1% HCOOH was
added to each test sample. Protein identification by
MALDI-Q-TOF-MS [51] was performed at the Proteomics
Core Facility of the Institute of Biological Chemistry,BMC Genomics 2008, 9:479 http://www.biomedcentral.com/1471-2164/9/479
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Academia Sinica. The MS data with monoisotopic peptide
masses were searched against the NCBI protein database
with use of the MASCOT search engine (Matrix Science;
London, UK). Variable modifications, methionine oxida-
tion and cysteine carbamidomethylation were taken into
account in our data analyses.
Western blot analysis
Total protein was isolated from test iDCs with ice-cold
lysis buffer (150 mM NaCl, 0.5% Triton X-100, 50 mM
Tris-HCl (pH 7.4), 20 mM EGTA, 1 mM dithiothreitol
(DTT), and protease inhibitor cocktail tablets) for 10
min and centrifuged at 12,000 × g for 20 min. Protein
samples were subjected to western blotting as described
previously [52]. Briefly, the proteins were detected after
overnight incubation at 4°C with 1:1000 dilution of
Mn-SOD or cofilin polyclonal antibodies (Millipore,
MA, USA). Equal protein loading was assessed using
mouse β-actin (Sigma Chemical Co., St. Louis, U.S.A).
The proteins were visualized with an enhanced chemi-
luminescence (ECL) detection kit (Amersham Pharma-
cia Biotech,       Buckinghamshire, UK).
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